CY1105549T1 - Καινουργια μεθοδος θεραπειας - Google Patents

Καινουργια μεθοδος θεραπειας

Info

Publication number
CY1105549T1
CY1105549T1 CY20061100125T CY061100125T CY1105549T1 CY 1105549 T1 CY1105549 T1 CY 1105549T1 CY 20061100125 T CY20061100125 T CY 20061100125T CY 061100125 T CY061100125 T CY 061100125T CY 1105549 T1 CY1105549 T1 CY 1105549T1
Authority
CY
Cyprus
Prior art keywords
treatment
new method
mag
administering
treating
Prior art date
Application number
CY20061100125T
Other languages
Greek (el)
English (en)
Inventor
Elaine Alison Irving
Mary Vinson
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of CY1105549T1 publication Critical patent/CY1105549T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
CY20061100125T 2001-02-08 2006-02-01 Καινουργια μεθοδος θεραπειας CY1105549T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0103174.9A GB0103174D0 (en) 2001-02-08 2001-02-08 Novel method of treatment
PCT/GB2002/000551 WO2002062383A2 (en) 2001-02-08 2002-02-08 Antagonists of myelin-associated glycoprotein and their use in the treatment and/or prevention of neurological diseases

Publications (1)

Publication Number Publication Date
CY1105549T1 true CY1105549T1 (el) 2010-07-28

Family

ID=9908386

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061100125T CY1105549T1 (el) 2001-02-08 2006-02-01 Καινουργια μεθοδος θεραπειας

Country Status (11)

Country Link
US (2) US20040170627A1 (enExample)
EP (2) EP1357941B1 (enExample)
JP (2) JP5005156B2 (enExample)
AT (1) ATE314861T1 (enExample)
AU (1) AU2002229928A1 (enExample)
CY (1) CY1105549T1 (enExample)
DE (1) DE60208534T2 (enExample)
DK (1) DK1357941T3 (enExample)
ES (1) ES2254655T3 (enExample)
GB (1) GB0103174D0 (enExample)
WO (1) WO2002062383A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0103174D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Plc Novel method of treatment
US20040151721A1 (en) 2001-10-19 2004-08-05 O'keefe Theresa Humanized anti-CCR2 antibodies and methods of use therefor
AR040778A1 (es) * 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
GB0306309D0 (en) * 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment
EP3211084B1 (en) * 2003-05-16 2019-03-27 Acorda Therapeutics, Inc. Proteoglycan degrading mutants for treatment of cns
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
WO2005060368A2 (en) * 2003-12-10 2005-07-07 Millennium Pharmaceuticals, Inc. Humanized anti-ccr2 antibodies and methods of use
WO2007038548A2 (en) 2005-09-26 2007-04-05 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase abci mutants
US20100189721A1 (en) * 2007-07-06 2010-07-29 Smithkline Beecham Corporation Antibody formulations
US8974782B2 (en) 2011-02-07 2015-03-10 Glaxo Group Limited Treatment of stroke comprising anti-MAG antibodies

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873316A (en) * 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5250414A (en) * 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5154924A (en) * 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5527527A (en) * 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5182107A (en) * 1989-09-07 1993-01-26 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
GB9403250D0 (en) * 1994-02-21 1994-04-13 Univ Mcgill Therapeutic use of myelin-associated glycoprotein (mag)
US6576607B1 (en) * 1995-04-19 2003-06-10 Acorda Therapeutics Methods using CNS neurite outgrowth modulators
US5792743A (en) * 1995-04-19 1998-08-11 Acorda Therapeutics Method for promoting neural growth comprising administering a soluble neural cell adhesion molecule
DE69633336T2 (de) * 1995-06-27 2005-09-22 Research Foundation Of Cuny Zusamenzetzung enthaltend einen inhibitor des myelin assoziierten glycoproteins (mag), welcher einer veränderten oder mutierten form von mag enthält
DE69818106T2 (de) * 1997-10-28 2004-06-17 The University Of British Columbia, Vancouver Immunologische zusammensetzungen und verfahren zur transienten änderung des zentralnervensystem-myelins der saügetiere und förderung der nerven-regenerierung
JP2002507544A (ja) * 1997-11-14 2002-03-12 ユーロ−セルティーク，エス．エイ． 抗イディオタイプ応答を引き出す能力が増強された改変型の抗体
AU3134799A (en) * 1998-04-16 1999-11-08 Peter Erich Braun Nevron growth inhibitory molecules or derivatives thereof used to immunize mammals thereby promoting axon regeneration
GB9908533D0 (en) * 1999-04-14 1999-06-09 Novartis Ag Organic compounds
GB0103174D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Plc Novel method of treatment
US20040002790A1 (en) * 2002-06-28 2004-01-01 Paul Senn Sensitive devices and sensitive applications
AR040778A1 (es) * 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
GB0306309D0 (en) * 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment

Also Published As

Publication number Publication date
US20040170627A1 (en) 2004-09-02
DK1357941T3 (da) 2006-05-01
EP1357941A2 (en) 2003-11-05
JP2004523538A (ja) 2004-08-05
AU2002229928A1 (en) 2002-08-19
JP5005156B2 (ja) 2012-08-22
EP1357941B1 (en) 2006-01-04
US20080014195A1 (en) 2008-01-17
EP1645285A2 (en) 2006-04-12
ES2254655T3 (es) 2006-06-16
WO2002062383A2 (en) 2002-08-15
WO2002062383A3 (en) 2003-04-10
ATE314861T1 (de) 2006-02-15
JP2008291031A (ja) 2008-12-04
DE60208534T2 (de) 2006-11-30
DE60208534D1 (de) 2006-03-30
EP1645285A3 (en) 2010-04-14
GB0103174D0 (en) 2001-03-28

Similar Documents

Publication Publication Date Title
CY1119353T1 (el) Θεραπευτικη χρηση αντισωματων anti-cs1
CY1118429T1 (el) Αντισωμα συνδεσης αλφα4βητα7 ιντεγκρινης και η χρηση αυτου εις τη θεραπευτικη αγωγη της φλεγμονωδους νοσου του εντερου
EA200501891A1 (ru) Гуманизированные антитела, распознающие бета-амилоидный пептид
CY1107087T1 (el) Μιμητικα θρομβοποιητινης
ECSP034685A (es) Anticuerpos humanizados que reconocen el peptido amiloideo beta
UA111707C2 (uk) Застосування виділеного анти-tnf-альфа антитіла людини
EP1613347A4 (en) BETA AMYLOID PEPTIDE DETECTING HUMANIZED ANTIBODIES
CY1120070T1 (el) Μεθοδοi θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος εναντι-erbb-μεϋτανσινοειδους
DE69932084D1 (de) Antikörperfragmente zur lokalen Behandlung von Augenerkrankungen
DK1385864T3 (da) Anti-VEGF-2-antistoffer
PL401886A1 (pl) Neutralizujace o wysokim powinowactwie izolowane ludzkie przeciwcialo anty-TNF-alfa, zastosowanie tego przeciwciala, krysztal zawierajacy ludzkie przeciwcialo anty-TNF-alfa i preparat zawierajacy ten krysztal
ATE482722T1 (de) Therapeutische verwendung von anti-cs1- antikörpern
ATE353657T1 (de) Verwendung von immunerregenden oligonukleotiden zur vorbeugung oder behandlung von asthma
CY1108765T1 (el) ΑΓΩΓΗ ME ΑΝΤΙΣΩΜΑΤΑ ANTI-ErbB2
DK1212422T3 (da) Humane CTLA-4-antistoffer og anvendelserne deraf
CY1111725T1 (el) ΧΙΜΑΙΡΙΚΕΣ ΠΡΩΤΕÏΝΕΣ ΠΑΡΑΓΟΝΤΑ ΠΗΞΗΣ VII-Fc ΓΙΑ ΤΗ ΘΕΡΑΠΕΙΑ ΜΙΑΣ ΑΙΜΟΣΤΑΤΙΚΗΣ ΔΙΑΤΑΡΑΧΗΣ
EA200501560A1 (ru) Предотвращение и терапия амилоидогенной болезни
DE60027732D1 (de) Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems
CY1107314T1 (el) Μεθοδος θεpαπευτικης αγωγης ασθενων προσβεβλημενων με σκληρυνση κατα πλακας χρησιμοποιωντας συναινετικη ιντepφepονη
CY1105549T1 (el) Καινουργια μεθοδος θεραπειας
IS6105A (is) Aðferð til meðferðar á netjuhersli með notkun mótlyfs við integríninu alfa-4
ATE495751T1 (de) Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
MX9706588A (es) Metodo para estimular una respuesta inmune.
ATE357912T1 (de) Intrakorporelle medikamente zur hoch- energetischen phototherapeutischen behandlung von krankheiten
CY1115003T1 (el) Θεραπευτικη χρηση των αντισωματων αντι-cs1